Cartesian Therapeutics to Launch In Vivo CAR-T Trial in Myasthenia Gravis 2H 2026
RNAC•Cartesian Therapeutics has licensed WestGene’s targeted LNP platform to deliver its Descartes-08 mRNA payload, integrating two clinically tested technologies for in vivo CAR-T therapy development. The Phase 1 myasthenia gravis trial is slated for 2H 2026 with clinical proof-of-concept data expected in 1H 2027.
1. Licensing Agreement Overview
Cartesian Therapeutics has entered a licensing agreement with WestGene Biopharma to use its targeted lipid nanoparticle (tLNP) platform to deliver Cartesian’s Descartes-08 mRNA payload, combining two clinically validated technologies to enable in vivo CAR-T therapy for autoimmune diseases.
2. Technology Synergy and Pipeline Expansion
WestGene’s tLNP platform supports repeated dosing with a favorable safety profile and demonstrated robust in vivo CAR-T generation, while Cartesian plans to advance multiple next-generation anti-BCMA CAR constructs and a BCMA-directed T-cell engager using this delivery system.
3. Clinical Development Timeline
The partnership will initiate a Phase 1 dose-escalation study in myasthenia gravis patients in 2H 2026, employing a Bayesian Optimal Interval design, with clinical proof-of-concept data expected in 1H 2027.
4. Financial Terms and Milestones
Under the agreement, WestGene will receive an upfront payment and is eligible for development and commercial milestone payments, providing Cartesian with an efficient framework to advance additional mRNA payloads into human trials.
